Foundery Innovations Establishes Scientific Advisory Board with Appointment of Key Opinion Leaders in Immunology and Oncology
Retrieved on:
Tuesday, March 28, 2023
SAB, Infection, University of California, San Diego, Maintenance, KOL, Human, University, Therapy, Biochemistry, Government Medical College, Texas A&M University, Biotechnology, UCSF Helen Diller Family Comprehensive Cancer Center, Research, Joslin Diabetes Center, Immunotherapy, Biology, Melanoma, Genentech, Translation, Harvard Medical School, Aix-Marseille University, Malignancy, School of Biological Sciences, University of Manchester, UCSF, Pathology, SAN, University of Washington Department of Bioengineering, School, Immune system, ILC2, Protein engineering, Knowledge, Entrepreneurship, Mouse, Cytokine, Health, Gene, Disease, Pharmaceutical industry, Vaccine, The Foundery
SAN FRANCISCO, March 28, 2023 (GLOBE NEWSWIRE) -- Foundery Innovations (“Foundery”), a biotechnology venture studio focused on translating immunology discoveries into drug candidates, announced the establishment of its scientific advisory board (“SAB”) with the appointments of key opinion leaders (“KOLs”) in immunology, oncology, and protein engineering.
Key Points:
- SAN FRANCISCO, March 28, 2023 (GLOBE NEWSWIRE) -- Foundery Innovations (“Foundery”), a biotechnology venture studio focused on translating immunology discoveries into drug candidates, announced the establishment of its scientific advisory board (“SAB”) with the appointments of key opinion leaders (“KOLs”) in immunology, oncology, and protein engineering.
- Dr. Locksley’s laboratory pioneered the use of mice genetically engineered to express cytokines during allergic immune responses.
- Foundery is in discussions with a handful of other KOLs and looks forward to announcing them in the coming months.
- Additionally, Foundery’s scientific advisor pool is expected to grow in parallel with the Company’s portfolio expansion.